{
    "nct_id": "NCT06616597",
    "official_title": "Phase II Trial Targeting Gut Bacterial Androgen Production to Reverse Therapeutic Resistance to Abiraterone in Patients With Metastatic Prostate Cancer",
    "inclusion_criteria": "* Males aged 18 years of age and above.\n* Prostate adenocarcinoma\n* Absolute PSA ≥ 2.0 ng/mL at screening.\n* PSA (+/- radiographic) progression after having been on abiraterone and prednisone for at least 12 weeks.\n* Must be maintained on a GnRH analogue or have undergone orchiectomy.\n* Participants must have a life expectancy ≥ 6 months\n* Ability to swallow study medication tablets\n* Willing to abstain from alcohol during and for 14 days after treatment with metronidazole\n* Willing and able to collect urine and stool samples per protocol\nHealthy volunteers allowed\nMust be MALE\nMust have minimum age of 18 Years",
    "exclusion_criteria": "* Active infection or other medical condition that would make dexamethasone use contraindicated\n* Any chronic medical condition requiring a higher systemic dose of corticosteroid\n* Pathological finding consistent with small cell carcinoma of the prostate\n* Has imminent or established spinal cord compression based on clinical findings and/or MRI.\n* Chronic liver disease with Child-Pugh class C cirrhosis (see calculator in protocol)\n* Bilirubin &gt;3x ULN or AST and ALT &gt;5x ULN\n* Congenital prolonged QTc syndrome or QTc &gt; 500 msec (non-paced rhythm)\n* History of pituitary or adrenal dysfunction\n* Uncontrolled diabetes (Hemoglobin A1c &gt; 10%) or increasing doses of insulin within the past 4 weeks due to poorly controlled glucoses.\n* Administration of an investigational therapeutic or invasive surgical procedure (not including surgical castration) within 30 days of Cycle 1 Day 1 or currently enrolled in an investigational drug study\n* Any other serious illness or medical condition that would, in the opinion of the investigator, make this protocol unreasonably hazardous, including, but not limited to:\n\n  * Any uncontrolled major infection.\n  * Crohn's disease or ulcerative colitis.\n  * Known or suspected toxic megacolon and/or known small bowel ileus.\n  * Known allergy to any of the compounds under investigation.\n* On antibacterial therapy within 30 days prior to administration of study treatment.\n* Any condition or situation which, in the opinion of the investigator, would put the subject at risk, or interfere with the subject's participation in this study.",
    "miscellaneous_criteria": ""
}